Skip to content

Company

Isomorphic Labs

Isomorphic Labs is an Alphabet-owned, DeepMind-spun-out company using AI models to design new drugs and accelerate pharmaceutical discovery.

Known aliases

  • Isomorphic
  • Isomorphic Labs Ltd.

Current stories

investConfirmed5 publishers

Isomorphic Labs seeks a $40 billion valuation before its first human trial

Alphabet's Isomorphic Labs is in funding talks at a $40 billion valuation. Crypto Briefing put its prior mark near $17.5 billion, so the ask more than doubles the price of a drug designer that has yet to dose a patient.

Perspective Coverage

6 publishers
Builder
Builder 26%
Operator
Operator 17%
Investor
Investor 57%

Reality

Evidence55
Adoption25
Hype gap+45
Incentives55
Confidence55
investConfirmed11 publishers

Meta, DeepMind and Isomorphic pay $300 million for first use of Biohub's open cell data

Meta, Google DeepMind and Isomorphic Labs put $300 million into Biohub's $1.8 billion Virtual Biology Initiative and get the data before the public does. Startups that sell proprietary cell data will now be priced against a free dataset that their best-funded rivals see first.

Perspective Coverage

13 publishers
Builder
Builder 41%
Operator
Operator 31%
Investor
Investor 28%

Reality

Evidence66
Adoption18
Hype gap+35
Incentives72
Confidence62
productOne report1 publisher

Brin shapes Gemini's model sizes and release windows from a converted microkitchen

Business Insider, citing eight current and former employees, reports that Google's cofounder holds no executive title while making technical calls on Gemini from a desk the new DeepMind SVP shares. Google declined to comment.

Publishers:thenextweb.com

Reality

Evidence40
Adoption
Not scored
Hype gap+14
Incentives62
Confidence38
scienceOne report1 publisher

IITGN clones the four stigma genes behind toria's rejection of its own pollen

The work is careful basic genetics: cloned sequences, predicted protein folds, and one gene switched off at a time. Whether it touches India's 56% edible oil import share depends on breeding that has not happened yet.

Publishers:phys.org

Reality

Evidence58
Adoption12
Hype gap+30
Incentives68
Confidence55
productOne report1 publisher

Insilico credits its AI with a drug discovery. The patent credits five humans.

Only people can be inventors under US law, so the file on an AI-derived molecule has to show human contribution. Teams that do not document it are building patents someone can challenge.

Reality

Evidence56
Adoption44
Hype gap+22
Incentives66
Confidence58
productOne report1 publisher

Vivodyne says the AI drug bottleneck is human tissue data, not model capability

The startup opened what it calls the world's largest human data center last week. Its diagnosis of the field is testable; most of the evidence for its own machines is self-reported.

Publishers:techcrunch.com

Reality

Evidence34
Adoption27
Hype gap+32
Incentives76
Confidence44
investOne report1 publisher

CoreWeave's $104bn backlog is now a margin question, not a demand question

Management says scale is starting to show up as operating leverage. The release as supplied gives a backlog, power figures and more than $14bn of fresh capital, but no margin numbers.

Publishers:investors.coreweave.com

Reality

Evidence42
Adoption71
Hype gap+32
Incentives88
Confidence55